This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goedegebuure, P. S. Articles by Eberlein, T. J. Search for Related Content PubMed PubMed Citation Articles by Goedegebuure, P. S. Articles by Eberlein, T. J.

Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors

Laboratory of Biologic Cancer Therapy, Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Peter S. Goedegebuure, Ph.D., Division of Surgical Oncology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. Telephone: 617-732-6247; Fax: 617-278-6914; e-mail: psgoedegeb{at}bics.bwh.harvard.edu

Recent progress in tumor genetics, tumor biology, and tumor immunology has renewed interest in the development of tumor vaccines. Unlike the previous generation of vaccines that consisted of the patient’s own tumor cells in some form, the new vaccines contain defined peptides or genes with a known function. In order to induce a potent and long-lasting cell-mediated antitumor response, viral as well as nonviral vectors have been explored as vehicles for gene delivery. Both types of vectors have shown encouraging results in animal models. However, because of the many possible vectors that have been designed, it may be too early to say which type of vector is most efficient in the human. Clearly, viral vectors have a higher transduction efficiency than most nonviral delivery systems. A drawback is that viral vectors may be toxic or immunogenic. Current research focuses on enhancing the targeting and specificity of both viral and nonviral vectors and control of transgene expression levels. Clinical studies using a variety of both viral and nonviral vectors have begun, and the results are forthcoming.

Key Words. Human • Cancer • Vaccine • Vector • T lymphocyte • Immune response